INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 57 filers reported holding INFINITY PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $14,000 | -6.7% | 14,176 | 0.0% | 0.00% | – |
| Q3 2019 | $15,000 | -42.3% | 14,176 | 0.0% | 0.00% | – |
| Q2 2019 | $26,000 | -3.7% | 14,176 | 0.0% | 0.00% | – |
| Q1 2019 | $27,000 | +58.8% | 14,176 | 0.0% | 0.00% | – |
| Q4 2018 | $17,000 | -55.3% | 14,176 | 0.0% | 0.00% | – |
| Q3 2018 | $38,000 | +40.7% | 14,176 | 0.0% | 0.00% | – |
| Q2 2018 | $27,000 | -10.0% | 14,176 | 0.0% | 0.00% | – |
| Q1 2018 | $30,000 | +3.4% | 14,176 | 0.0% | 0.00% | – |
| Q4 2017 | $29,000 | -70.4% | 14,176 | -80.8% | 0.00% | -100.0% |
| Q3 2017 | $98,000 | +28.9% | 73,916 | +51.9% | 0.00% | +100.0% |
| Q2 2017 | $76,000 | -31.5% | 48,666 | +41.1% | 0.00% | -50.0% |
| Q1 2017 | $111,000 | +136.2% | 34,490 | 0.0% | 0.00% | +100.0% |
| Q4 2016 | $47,000 | – | 34,490 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,354,963 | $38,132,000 | 1.80% |
| Orbimed Advisors | 4,520,800 | $73,201,000 | 1.55% |
| QVT Financial LP | 1,326,610 | $21,480,000 | 1.44% |
| BB BIOTECH AG | 1,089,828 | $17,646,000 | 1.27% |
| Meditor Group Ltd | 250,000 | $4,048,000 | 0.55% |
| Perimeter Capital Partners, LLC | 159,915 | $2,589,000 | 0.50% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 156,808 | $2,539,000 | 0.43% |
| Broadfin Capital, LLC | 117,172 | $1,897,000 | 0.37% |
| OXFORD ASSET MANAGEMENT LLP | 811,331 | $13,184,000 | 0.36% |
| Baker Brothers Advisors | 1,016,433 | $16,458,000 | 0.33% |